(secondQuint)Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis.

 This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix JV, LLC (BMX).

 It is a double-blind parallel cohort study designed to determine the safety and efficacy of BMX-010 (0.

03%) relative to Placebo in subjects with atopic dermatitis and psoriasis.

 Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.

.

 Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis@highlight

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis.

 In this trial BMX-010 will be topically applied twice daily for up to 28 days.

